Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the RESILIENT-1 and NeoADAURA trials.

The trial is being carried out in 16 nations and regions, including Asia, North America, Europe, and South America.

The study is the first, to the researchers’ knowledge, to evaluate both survival and cost metrics across non-small cell lung ...

The Lung Cancer Research Foundation (LCRF) announces today a new funding mechanism: the 2025 LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The Request for ...

On April 29, 2025, Vivoryon disclosed preclinical data from a series of experiments in a chronic kidney disease animal model, analyzing different treatment regimens of varoglutamstat in combination ...

Oncology nurses can play a key role in educating patients and supporting clinical trial participation for this new treatment ...

Treatments for multiple myeloma, melanoma, NSCLC, phenylketonuria, C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis are under review.

Dr Amit Rauthan, Head, Department and Consultant, Medical Oncology and Hemato-Oncology, Manipal Hospital, explains how the advancements in oncology are offering hope by transforming cancer into a more ...

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Cancer patients found to have specific gene mutations or other biomarkers are being matched to precision treatments not ...